Le Lézard
Classified in: Health, Science and technology
Subject: FDA

NeuraLace Announces FDA 510(k) Clearance and U.S. Launch of Axon Therapy® Peripheral Nerve Stimulation System For Chronic Pain Relief

SAN DIEGO, June 17, 2021 /PRNewswire/ -- NeuraLace Medical, Inc., a medical device company focused on improving pain relief among patients suffering from debilitating chronic pain, announced today that it has received FDA 510(k) clearance for Axon Therapy® to non-invasively stimulate peripheral nerves and provide chronic nerve pain relief. 

"After 10 years of R&D, we are pleased to have received FDA 510(k) clearance for Axon Therapy and we're incredibly excited to bring to market a non-opioid treatment option that provides meaningful relief for patients suffering from chronic pain," said Shiv Shukla, Founder and CEO of NeuraLace Medical. "We believe Axon Therapy is a significant step forward on the care continuum that is accessible to patients today and we look forward to bringing sustainable pain relief to patients by launching Axon Therapy in the United States."

"Existing options to treat chronic nerve pain can be ineffective, addictive and invasive." Said Executive Chairman, Sean Edwards. "We're excited to offer patients a method of relief that is non-addictive and non-invasive."

Axon Therapy delivers focused magnetic pulses which activate the damaged peripheral nerve axons that are required to provide relief from chronic nerve pain. The Axon Therapy coil, connected to a compact stimulation module, produces strong magnetic pulses near the injured nerve during the course of the treatment. NeuraLace's patented low frequency waveform leverages the principles of electromagnetic induction to create a voltage differential that elicits neuronal stimulation in the axon of the damaged nerve resulting in pain relief. Current forms of neuromodulation focus on masking the transmission of pain signals, whereas Axon Therapy seeks to suppress the pain signal by re-activating the body's natural modulatory mechanism, which is dormant after traumatic injury to the nerve.

Privately held NeuraLace Medical, Inc., headquartered in San Diego, Calif., is committed to leading the charge in non-invasive chronic pain management and sustainable relief.  Our mission to end chronic pain inspired us to develop Axon Therapy, with the goal of being the first non-invasive, non-addictive way to effectively treat chronic nerve pain.  

Axon Therapy® and the NeuraLace logo are trademarks of NeuraLace Medical, Inc.

Inquiries: hello@neuralacemedical.com or 858-232-0779.

Follow NeuraLace on LinkedIn and Twitter at @Neuralace.

SOURCE Neuralace Medical, Inc.

These press releases may also interest you

at 18:00
The National Safety Council Southeastern Chapter (SCNSC) and State Farm are partnering with SC Highway Patrol and local law enforcement agencies to remind South Carolina teen drivers that distracted driving can be deadly. During National Teen Driver...

at 16:20
In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however, signs of reduced disease progression across multiple...

at 16:20
Ionis Pharmaceuticals, Inc. partner Biogen today announced topline results from its placebo-controlled pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense medicine being evaluated for people with superoxide dismutase 1...

at 13:00
Amazfit today announced that Target stores nationwide will now carry an even greater assortment of fitness trackers combining sports functionality and health management into one simple-to-use and affordable tracker. The Bip U Pro and Band 5 will now...

at 12:00
M Accelerator invites founders and investors to join Pitch Day & Talks Fall 2021, a one-day online event hyper-focused on founders and the company's growth strategy. M Accelerator, an innovative program based in Los Angeles, helps founders boost and...

at 11:23
Wemlo,SM the first third-party mortgage processing solution with an award-winning all-in-one digital platform, today announced the upcoming launch of an innovative new technology that aims to transform the mortgage brokerage industry....

News published on 17 june 2021 at 10:37 and distributed by: